Investigation for Investors in Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) Announced

An investigation for investors in NASDAQ:SGEN shares over potential securities laws violations by Seattle Genetics, Inc. was announced and NASDAQ:SGEN stockholders should contact the Shareholders Foundation.

Logo

San Diego, CA -- (SBWire) -- 01/04/2017 --An investigation on behalf of investors in NASDAQ:SGEN shares was announced concerning possible securities laws violations by Seattle Genetics.

Investors who purchased shares of Seattle Genetics, Inc. (NASDAQ:SGEN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements by Seattle Genetics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On December 27, 2016, Seattle Genetics, Inc. (NASDAQ:SGEN) announced that it has received notice from the U.S. Food and Drug Administration ("FDA") that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML). Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) declined on December 27, 2016 to as low as $51.63 per share.

On January 3, 2016, NASDAQ:SGEN shares closed at $53.00 per share.

Those who purchased shares of Seattle Genetics, Inc. have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

Media Relations Contact

Michael Daniels
General Manager
Shareholders Foundation
858-779-1554
http://www.ShareholdersFoundation.com

View this press release online at: http://rwire.com/756402